Does Nektar Therapeutics (NKTR) Have Insiders Selling Shares?


As of Friday close, Nektar Therapeutics’s (NASDAQ:NKTR) stock was down -$0.14, moving down -12.49 percent to $0.98. The average number of shares traded per day over the past five days has been 3,286,360 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.2099 fall in that time frame. In the last twenty days, the average volume was 3,664,135, while in the previous 50 days, it was 2,296,492.

Since last month, NKTR stock retreated -68.49%. Shares of the company fell to $0.9600 on 03/17/23, the lowest level in the past month. A 52-week high of $6.39 was reached on 02/07/23 after having rallying from a 52-week low of $1.08. Since the beginning of this year, NKTR’s stock price has dropped by -56.63% or -$1.2799, and marked a new high 15 times. However, the stock has declined by -84.67% since its 52-week high.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


NKTR stock investors should be aware that Nektar Therapeutics (NKTR) stock had its last reported insider trading activity 30 days ago on Feb 16. ROBIN HOWARD W, the President & CEO of the company, disposed of 19,635 shares for $3.00 on Feb 16. It resulted in a $58,905 divestment by the insider. Zalevsky Jonathan sold 10,484 shares at an average price of $3.00 on Feb 16. The insider now owns 303,179 shares following the transaction. On Feb 16, Chief Financial Officer Thomsen Jillian B. sold 10,267 shares at $3.00 apiece. The transaction was valued at $30,801.

Valuation Metrics

The stock’s beta is 1.17. Besides these, the trailing price-to-sales (P/S) ratio of 2.06, the price-to-book (PB) ratio of 0.50.

Financial Health

In the three months ended September 29, Nektar Therapeutics’s quick ratio stood at 7.70, while its current ratio was 8.00, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 76.50% percent. Based on annual data, NKTR earned $70.42 million in gross profit and brought in $92.06 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -103.50%. Return on equity (ROE) for the past 12 months was -79.80%.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. NKTR’s revenue fell -13.58% to $23.63 million during the quarter, while net income inched up to $22.02 million. While analysts expected Nektar Therapeutics to report -$0.45 quarterly earnings, the actual figure was -$0.31 per share, beating the consensus estimate by 31.10%. During the quarter, the company generated -$48.91 million in EBITDA. The liabilities of Nektar Therapeutics were 343.96 million at the end of its most recent quarter ended September 29, and its total debt was $134.65 million. The value of shareholders’ equity is $189.24 million.

Technical Picture

This quick technical analysis looks at Nektar Therapeutics’s (NKTR) price momentum. With a historical volatility rate of 54.68%, the RSI 9-day stood at 15.72% on 17 March.

With respect to its five-day moving average, the current Nektar Therapeutics price is down by -17.64% percent or -$0.2099. At present, NKTR shares trade -67.11% below its 20-day simple moving average and -71.92% percent below its 100-day simple moving average. However, the stock is currently trading approximately -58.12% below its SMA50 and -71.84% below its SMA200.

Stochastic coefficient K was 4.49% and Stochastic coefficient D was 3.71%, while ATR was 0.1539. Given the Stochastic reading of 3.14% for the 14-day period, the RSI (14) reading has been calculated as 21.78%. As of today, the MACD Oscillator reading stands at -0.1033, while the 14-day reading stands at -0.2121.

Analyst Ratings

Nektar Therapeutics downgraded its rating on Nektar Therapeutics (NASDAQ: NKTR) to an Underperform in a note to investors on February 24, 2023. The analysts firm previously had a Hold rating on the stock.Nektar Therapeutics (NKTR) has been rated Underweight by analysts. According to 3 brokerage firms, NKTR is a sell, and 7 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 0 analysts rate Nektar Therapeutics stock as buy, with 0 recommending it as overweight.

With a median target price of $3.00, the current consensus forecast for the stock is $1.50 – $6.00. Based on these forecasts, analysts predict Nektar Therapeutics (NKTR) will achieve an average price target of $2.93.


Please enter your comment!
Please enter your name here